US › Healthcare

Vyome Holdings, Inc. (HIND)

US · Healthcare · Biotechnology

$1.87-2.09%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$26,955

Revenue YoY

-97.8%

Net profit

$-685,556

EPS

$-0.10

EPS estimate

$-0.19

Net margin

-2,543.3%

EPS came in at -0.10 against a street estimate of -0.19 — a beat of 47.4%.

Key statistics

Market cap

$13.8M

P/E

1.1

Forward P/E

0.0

P/B

2.31

Book value

$0.86

EPS (TTM)

$1.78

52-week high

$6.56

52-week low

$1.75

50-day MA

$2.11

200-day MA

$2.35

Analyst view

Analysts rate Vyome Holdings, Inc. a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $8.83.

Shareholding

Insiders

52.88%

Institutions

2.18%

Largest institutional holders

Fund	Stake
Citadel Advisors Llc	0.37%
Geode Capital Management, LLC	0.37%
HRT FINANCIAL LLC	0.29%
The Colony Group LLC	0.21%
Vanguard Fiduciary Trust Co	0.17%
UBS Group AG	0.17%
Susquehanna International Group, LLP	0.14%
Vanguard Capital Management, LLC	0.13%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vyome Holdings, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.